Advertisement
Screener

Lantheus Holdings, Inc. (LNTH) Payments to Acquire Productive Assets

2.8 / 5 stars · 68/120 Roast Me

Lantheus Holdings, Inc. Payments to Acquire Productive Assets

Lantheus Holdings, Inc. (LNTH) reported Payments to Acquire Productive Assets of $45.34 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-22.

Discontinued › Cash Flow › Investing Activities

us-gaap:PaymentsToAcquireProductiveAssets · last filed 2024-02-22

  • Lantheus Holdings, Inc. payments to acquire productive assets for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
  • Lantheus Holdings, Inc. payments to acquire productive assets for the quarter ending 2023-09-30 was $0.00.
  • Lantheus Holdings, Inc. payments to acquire productive assets for the quarter ending 2023-06-30 was $10.00M.
  • Lantheus Holdings, Inc. payments to acquire productive assets for the quarter ending 2023-03-31 was $35.34M.
  • Lantheus Holdings, Inc. payments to acquire productive assets for fiscal 2023 was $45.34M, a 82.56% decline from fiscal 2022.
  • Lantheus Holdings, Inc. payments to acquire productive assets for fiscal 2022 was $260.00M.
  • Lantheus Holdings, Inc. payments to acquire productive assets for fiscal 2021 was $0.00.
  • Lantheus Holdings, Inc. payments to acquire productive assets for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
Period endPayments to Acquire Productive Assets 3 monthPayments to Acquire Productive Assets 3 month as first filedPayments to Acquire Productive Assets 6 monthPayments to Acquire Productive Assets 6 month as first filedPayments to Acquire Productive Assets 9 monthPayments to Acquire Productive Assets 9 month as first filedPayments to Acquire Productive Assets 12 monthPayments to Acquire Productive Assets 12 month as first filed
2023-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22
$0.00
derived: sum of 2 quarters · filed 2024-02-22
$10.00M
derived: sum of 3 quarters · filed 2024-02-22
$45.34M
10-K · filed 2024-02-22
2023-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02
$10.00M
derived: sum of 2 quarters · filed 2023-11-02
$45.34M
10-Q · filed 2023-11-02
$305.35M
derived: sum of 4 quarters · filed 2024-02-22
2023-06-30$10.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03
$45.34M
10-Q · filed 2023-08-03
$305.35M
derived: sum of 3 quarters · filed 2024-02-22
$305.35M
derived: sum of 4 quarters · filed 2024-02-22
2023-03-31$35.34M
10-Q · filed 2023-05-04
$295.35M
derived: sum of 2 quarters · filed 2024-02-22
$295.35M
derived: sum of 3 quarters · filed 2024-02-22
$295.35M
derived: sum of 4 quarters · filed 2024-02-22
2022-12-31$260.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22
$260.00M
derived: sum of 2 quarters · filed 2024-02-22
$260.00M
derived: sum of 3 quarters · filed 2024-02-22
$260.00M
10-K · filed 2024-02-22
2022-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02
$0.00
derived: sum of 2 quarters · filed 2023-11-02
$0.00
10-Q · filed 2023-11-02
$13.62M
10-Q · filed 2022-11-03
-$7.60M
derived: sum of 4 quarters · filed 2024-02-22
2022-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03
$0.00
10-Q · filed 2023-08-03
$7.53M
10-Q · filed 2022-08-04
-$7.60M
derived: sum of 3 quarters · filed 2024-02-22
-$5.18M
derived: sum of 4 quarters · filed 2024-02-22
2022-03-31$0.00
10-Q · filed 2023-05-04
$3.19M
10-Q · filed 2022-04-29
-$7.60M
derived: sum of 2 quarters · filed 2024-02-22
-$5.18M
derived: sum of 3 quarters · filed 2024-02-22
-$2.52M
derived: sum of 4 quarters · filed 2024-02-22
2021-12-31-$7.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22
-$5.18M
derived: sum of 2 quarters · filed 2024-02-22
-$2.52M
derived: sum of 3 quarters · filed 2024-02-22
$0.00
10-K · filed 2024-02-22
$12.14M
10-K · filed 2022-02-24
2021-09-30$2.42M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03
$5.08M
derived: sum of 2 quarters · filed 2022-11-03
$7.60M
10-Q · filed 2022-11-03
-$1.09M
derived: sum of 4 quarters · filed 2023-02-23
2021-06-30$2.66M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04
$5.18M
10-Q · filed 2022-08-04
-$3.51M
derived: sum of 3 quarters · filed 2023-02-23
$223.00K
derived: sum of 4 quarters · filed 2023-02-23
2021-03-31$2.52M
10-Q · filed 2022-04-29
-$6.17M
derived: sum of 2 quarters · filed 2023-02-23
-$2.43M
derived: sum of 3 quarters · filed 2023-02-23
-$178.00K
derived: sum of 4 quarters · filed 2023-02-23
2020-12-31-$8.69M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23
-$4.95M
derived: sum of 2 quarters · filed 2023-02-23
-$2.70M
derived: sum of 3 quarters · filed 2023-02-23
$0.00
10-K · filed 2023-02-23
$12.47M
10-K · filed 2021-02-25
2020-09-30$3.74M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04
$5.99M
derived: sum of 2 quarters · filed 2021-11-04
$8.69M
10-Q · filed 2021-11-04
$13.43M
derived: sum of 4 quarters · filed 2022-02-24
2020-06-30$2.25M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-28
$4.95M
10-Q · filed 2021-07-28
$9.69M
derived: sum of 3 quarters · filed 2022-02-24
$13.03M
derived: sum of 4 quarters · filed 2022-02-24
2020-03-31$2.70M
10-Q · filed 2021-05-04
$7.44M
derived: sum of 2 quarters · filed 2022-02-24
$10.78M
derived: sum of 3 quarters · filed 2022-02-24
$14.21M
derived: sum of 4 quarters · filed 2022-02-24
2019-12-31$4.74M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24
$8.08M
derived: sum of 2 quarters · filed 2022-02-24
$11.51M
derived: sum of 3 quarters · filed 2022-02-24
$22.06M
10-K · filed 2022-02-24
2019-09-30$3.34M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
$6.77M
derived: sum of 2 quarters · filed 2020-11-05
$17.32M
10-Q · filed 2020-11-05
$24.69M
derived: sum of 4 quarters · filed 2021-02-25
2019-06-30$3.43M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31
$13.98M
10-Q · filed 2020-07-31
$21.35M
derived: sum of 3 quarters · filed 2021-02-25
$26.36M
derived: sum of 4 quarters · filed 2021-02-25
2019-03-31$10.55M
10-Q · filed 2020-04-30
$17.92M
derived: sum of 2 quarters · filed 2021-02-25
$22.92M
derived: sum of 3 quarters · filed 2021-02-25
$28.55M
derived: sum of 4 quarters · filed 2021-02-25
2018-12-31$7.37M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25
$12.37M
derived: sum of 2 quarters · filed 2021-02-25
$18.00M
derived: sum of 3 quarters · filed 2021-02-25
$20.13M
10-K · filed 2021-02-25
2018-09-30$5.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31
$10.63M
derived: sum of 2 quarters · filed 2019-10-31
$12.77M
10-Q · filed 2019-10-31
$18.72M
derived: sum of 4 quarters · filed 2020-02-25
2018-06-30$5.63M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-25
$7.76M
10-Q · filed 2019-07-25
$13.71M
derived: sum of 3 quarters · filed 2020-02-25
$17.00M
derived: sum of 4 quarters · filed 2020-02-25
2018-03-31$2.13M
10-Q · filed 2019-04-30
$8.09M
derived: sum of 2 quarters · filed 2020-02-25
$11.38M
derived: sum of 3 quarters · filed 2020-02-25
$14.78M
derived: sum of 4 quarters · filed 2020-02-25
2017-12-31$5.95M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25
$9.24M
derived: sum of 2 quarters · filed 2020-02-25
$12.64M
derived: sum of 3 quarters · filed 2020-02-25
$17.54M
10-K · filed 2020-02-25
2017-09-30$3.29M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-30
$6.69M
derived: sum of 2 quarters · filed 2018-10-30
$11.59M
10-Q · filed 2018-10-30
$14.01M
derived: sum of 4 quarters · filed 2019-02-20
2017-06-30$3.40M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01
$8.30M
10-Q · filed 2018-08-01
$10.72M
derived: sum of 3 quarters · filed 2019-02-20
$13.31M
derived: sum of 4 quarters · filed 2019-02-20
2017-03-31$4.90M
10-Q · filed 2018-05-02
$7.32M
derived: sum of 2 quarters · filed 2019-02-20
$9.91M
derived: sum of 3 quarters · filed 2019-02-20
$10.64M
derived: sum of 4 quarters · filed 2019-02-20
2016-12-31$2.42M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-20
$5.01M
derived: sum of 2 quarters · filed 2019-02-20
$5.75M
derived: sum of 3 quarters · filed 2019-02-20
$7.40M
10-K · filed 2019-02-20
2016-09-30$2.59M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02
$3.32M
derived: sum of 2 quarters · filed 2017-11-02
$4.98M
10-Q · filed 2017-11-02
$9.71M
derived: sum of 4 quarters · filed 2018-02-26
2016-06-30$736.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-01
$2.39M
10-Q · filed 2017-08-01
$7.12M
derived: sum of 3 quarters · filed 2018-02-26
$9.43M
derived: sum of 4 quarters · filed 2018-02-26
2016-03-31$1.65M
10-Q · filed 2017-05-02
$6.38M
derived: sum of 2 quarters · filed 2018-02-26
$8.69M
derived: sum of 3 quarters · filed 2018-02-26
$11.30M
derived: sum of 4 quarters · filed 2018-02-26
2015-12-31$4.73M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26
$7.04M
derived: sum of 2 quarters · filed 2018-02-26
$9.65M
derived: sum of 3 quarters · filed 2018-02-26
$13.15M
10-K · filed 2018-02-26
2015-09-30$2.31M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-01
$4.92M
derived: sum of 2 quarters · filed 2016-11-01
$8.42M
10-Q · filed 2016-11-01
$11.25M
derived: sum of 4 quarters · filed 2017-02-23
2015-06-30$2.61M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04
$6.11M
10-Q · filed 2016-08-04
$8.95M
derived: sum of 3 quarters · filed 2017-02-23
$10.77M
derived: sum of 4 quarters · filed 2017-02-23
2015-03-31$3.50M
10-Q · filed 2016-05-03
$6.33M
derived: sum of 2 quarters · filed 2017-02-23
$8.15M
derived: sum of 3 quarters · filed 2017-02-23
2014-12-31$2.83M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23
$4.66M
derived: sum of 2 quarters · filed 2017-02-23
$8.14M
10-K · filed 2017-02-23
2014-09-30$1.82M
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04
$5.30M
10-Q · filed 2015-11-04
2014-06-30$3.48M
10-Q · filed 2015-08-05
2013-12-31$5.01M
10-K · filed 2016-03-02

Similar stocks

Stock NameCountryMarket CapPE Ratio
NEOGEN CORP (NEOG)United States$2.979B-247.49
Celldex Therapeutics, Inc. (CLDX)United States$2.471B-9.72
Intellia Therapeutics, Inc. (NTLA)United States$1.705B-5.92
ACHIEVE LIFE SCIENCES, INC. (ACHV)United States$0.806B-5.88
QuidelOrtho Corp (QDEL)United States$0.733B-0.90
Alpha Teknova, Inc. (TKNO)United States$0.500B-18.12
MYRIAD GENETICS INC (MYGN)United States$0.397B-4.84
Insight Molecular Diagnostics Inc. (IMDX)United States$0.129B-3.90
IMMUCELL CORP /DE/ (ICCC)United States$0.091B116.10
BIOMERICA INC (BMRA)United States$0.011B